Bicycle Therapeutics implemented major workforce reductions, cutting approximately 30 percent of its total staff across its UK and US operations following regulatory setbacks regarding its lead oncology drug candidate. These strategic cutbacks—following an earlier round of redundancies—were designed to dramatically reduce annual operating expenses by nearly 50 percent and successfully extend the clinical-stage biopharmaceutical firm's cash runway out toward the year 2030.